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Abstract
Continuous positive airway pressure (CPAP) is the leading treatment for obstructive sleep apnoea
(OSA), a prevalent disorder of breathing in sleep strongly associated with obesity. OSA has serious
adverse health, social and community effects arising from disturbed breathing, loud snoring, poor
quality sleep and cardiovascular sequelae. When used appropriately, CPAP treatment is highly
effective in normalising breathing and sleep, improving symptoms and lowering adverse event risk.
However, patients do not necessarily accept, tolerate or comply with treatment, with many factors
influencing CPAP uptake and longer term use. Although knowledge to address challenges affecting
CPAP adherence and CPAP mask and machine technologies continue to improve incrementally,
optimising CPAP treatment adherence is an ongoing challenge in sleep medicine.
Introduction and context
Continuous positive airway pressure (CPAP) is the first-
line treatment for obstructive sleep apnoea (OSA), a
prevalent breathing disorder characterised by frequent
completeorpartialairwaycollapseeventsthatcanseverely
disrupt normal breathing and sleep. OSA patients are
usually overweight or obese and most frequently present
with debilitating daytime sleepiness or problematic
snoring affecting their bed partner. Left untreated, OSA is
associated with impaired daytime performance, an
increased risk of traffic and other accidents, hypertension,
neuropsychological disturbances, and metabolic dysfunc-
tion independent of obesity [1-5]. Although definitive
data are not yet available, cardiovascular and oxidative
stress associated with OSA also appear likely to contribute
to an increased risk of adverse cardiovascular events and
sudden death [6,7].
CPAP treatment utilises a pressurised mask to pneuma-
tically splint open and stabilise the upper airway during
sleep. While somewhat cumbersome and not without
side effects [8], CPAP is highly effective in normalising
breathing in sleep and consequently improving sleep
quality and daytime symptoms [9,10]. However, CPAP
only controls obstructed breathing events while an
appropriately pressurised mask remains in place, with a
single night of missed treatment sufficient for daytime
deficits to return [11]. In addition, while symptom
severity varies widely between patients, there are dose-
response relationships between average hours of nightly
use and the percentage of patients achieving normal
values in measures of daytime sleepiness and function
[12]. Studies showing improved survival in CPAP-
adherent patients [13], increased mortality in severe
untreated OSA irrespective of sleepiness [7], and reduced
blood pressure in non-sleepy OSA patients using CPAP
for most of every night [14] further support the need for
good compliance with effective treatments.
Despite strong evidence supporting the benefits and
effectiveness of CPAP, particularly in more severe cases,
as well as improved access to treatment and major
improvements in CPAP machine and mask technology
over the past three decades, patient adherence to
treatment frequently remains poor. Up to 50% of
patientsrecommendedCPAPmaynothavecommenced
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who commence CPAP,usemaybe intermittentand vary
considerably between and within nights over time. A
recent review suggests that 29-83% of patients average
less than 4 hours of CPAP use per night [17], a
somewhat arbitrary but the most frequent cut-off for
defining non-adherence based on minimal criteria for
adequate sleep [8,18]. Understanding the barriers to
and predictors of CPAP treatment uptake and long-term
adherence is therefore critical for successfully establish-
ing and maintaining patients on effective CPAP
treatment.
Recent advances
Treatment compliance monitoring
Modern CPAP machines provide objective measures of
time spent at pressure. Consequently, unlike many
treatments dependent on good patient co-operation,
objective measures of treatment compliance are readily
available. These are important for reliable monitoring
given that poor treatment adherence is not uncommon
in medicine and life-style interventions, that patients
frequently over-report CPAP treatment adherence
[18,19] and given the risks associated with untreated
severe OSA.
Predictors of CPAP compliance
Recent reviews examining predictors of CPAP adherence
highlight that many factors contribute to treatment
uptake and adherence over time [17,20,21]. Between 5
and 50% of patients recommended CPAP may simply
reject treatment before even trying or soon after pressure
titration and trial of CPAP, and a further 12-25% of
patients commencing CPAP abandon treatment within
3 years [16]. Apportioning the relative contribution of
factors contributing to adherence is difficult and
statistical associations are often relatively weak. Never-
theless, the severity of OSA and symptoms, the early
experience and effective trouble-shooting of treatment
problems and side effects, appropriate and timely
education and support, and behavioural and cost factors
appear to be the main predictors of uptake and long-
term compliance [16]. Differences in these factors
between studies likely account for widely divergent
CPAP rejection and adherence rates. Low initial rejec-
tion rates (~5%) are reported in a large series of patients
with symptomatic OSA [22], compared to high rejection
rates (~50%) in patients recommended CPAP on the
basis of an apnoea-hypopnoea index of greater than 15
events per hour, regardless of symptoms [23]. This is
consistent with symptom severity being a key determi-
nant of initial CPAP uptake, although other factors,
such as CPAP provision and follow-up practices, cannot
be discounted.
Disease severity and symptom relief
Symptom severity pre-treatment and symptom relief
with CPAP treatment are consistently amongst the
strongest predictors of CPAP compliance. Measures of
OSA severity per se appear more weakly associated with
CPAP adherence [16,17], although higher pressures are
also associated with lower compliance, perhaps indicat-
ing confounding by side effects [24]. Severe but
asymptomatic OSA patients show relatively low CPAP
compliance and few signs of any treatment benefit [25],
although increased mortality in untreated non-sleepy
OSA patients suggests that treatment adherence may
nevertheless confer benefit [7].
Side effects and complaints
Side effects and complaints are common, perhaps
affecting 30-70% of patients to varying degrees. In the
main these include inconvenience, poor mask fit and
discomfort, skin irritation, mask leaks and sore eyes,
airway drying, nasal problems, complaints of noise and
frequent awakening, claustrophobia, and dislike of CPAP
treatment [8,16,26]. With appropriate management, side
effects are unlikely to be a major impediment to
adherence [10,16], with a recent study suggesting that
health care personnel perceive side effects to be more of a
problem for adherence than do patients [27]. Patient
attitudes and behaviours may be a relatively more
important significant challenge to CPAP treatment
management.
Psychological factors
Some of the key determinants of CPAP rejection and
non-adherence may include apprehension regarding
how CPAP will make patients look and feel, interference
with normal life and sexual functioning, and other
behavioural or psychological factors [28]. Models
incorporating aspects of cognitive theory substantially
account for variance in CPAP adherence [29-31], likely
reflecting that behavioural and cognitive factors critically
influence patient decisions to seek, accept, and adhere to
treatment. The patient’s and their partner’s perceived
benefit are predictors of improved CPAP adherence
[16,32], while adherence is reduced if the patient’s
partner asked them to seek treatment (as opposed to the
patient initiating their own referral) [33] and if patients
sleep alone [34] or have a lower socioeconomic status
[35], anxiety or depression [36]. A recent study showing
higher lipid-lowering drug use in more CPAP compliant
patients supports that medication and CPAP adherence
behaviours are likely linked [37]. However, speculation
that generalised non-adherent behaviours may account
for poorer survival in CPAP non-adherent versus CPAP-
adherent OSA patients with cardiovascular disease was
challenged by a recent study showing no difference in
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non- or poorly adherent patients [38,39].
Early experience, education and support
Attitudes and beliefs as well as early problems and poor
initial CPAP usage are strongly predictive of longer-term
poor compliance [18,34,40-43]. Consequently, early
interventions targeting issues surrounding CPAP knowl-
edge, benefits and expectations, the initial novel
experience, and common problems of trying to sleep
with CPAP may be substantially alleviated via timely
education and clinical management [16,27,28,31,33,
44-47]. Adequate early education is clearly of major
importance for addressing psychosocial and behavioural
barriers to establishing effective CPAP treatment
[31,44,48]. Proper mask fit and early management of
technical problems such as nasal symptoms and air leak
are clearly important [49,50]. Humidification to resolve
airway drying may help improve compliance [51,52],
although evidence to support long-term benefit is still
lacking [20,21,53]. Data to compare patient compliance
between mask types are also very limited [54], but
appropriate mask choice and patient training are clearly
needed to ensure comfort and good fit. Some group data
support greater comfort and compliance with a nasal
versus face mask despite more mouth leak related
symptoms [55], although choice and fit tailored to
individual patients likely facilitates improved adherence
[54]. Some recent data suggest specific hypnotics used
during initial CPAP titration [56,57] and early CPAP use
[58] may help improve adherence in the short term by
facilitating sleep during early acclimation to CPAP.
However, hypnotics are already over-prescribed and
have attendant risks, some hypnotics could influence
OSA severity and CPAP titration, and there may be
increased daytime risks if treatment and/or compliance
remain suboptimal. Caution is therefore warranted with
early hypnotic use, particularly in the absence of longer
term outcome data.
Improving technologies
New masks and quiet, small and more sophisticated
positive airway pressure machines continue to emerge in
a competitive market. While the impact of new
technologies on patient preference and treatment adher-
ence remain largely to be established, there is some
evidence that improved mask comfort and algorithms
designed to modulate pressure to further improve
patient comfort are useful in some patients
[20,51,59,60]. However, the incremental benefits of
auto-adjusting devices appear to be small [20,61] and
treatment cost appears likely to be a significant barrier to
uptake. While further trials are needed, new technologies
allowing telemonitoring of CPAP compliance and
efficacy appear likely to be useful for simplifying
early intervention to address treatment problems and
adherence [45].
Strategies to improve compliance
Several recent studies show that CPAP adherence can be
improved using strategies to address problems and
barriers to patient acceptance and long-term treatment
adherence [20,44,51,57,62]. For example, one study
found 24% of 204 previously non-adherent patients
became adherent following interventions to improve
mask fit and comfort, nasal symptoms, and patient
education, with a further 38% of persistently non-
adherent patients continuing follow-up achieving adher-
encewith secondaryinterventions [51].Further systematic
and longer-term data concerning CPAP implementation
strategies are still needed to inform best practice for
optimising long-term CPAP adherence [9,63]. Never-
theless, appropriate education and behavioural interven-
tions are clearly important. Attitudes and beliefs are
known to be key determinants of treatment adherence
with other therapies [16], and available evidence indicates
thatthesameistrueforCPAP[28,29].Consequently,early
interventions to address knowledge gaps, set realistic
treatment expectations, and modify behavioural barriers
to establishing effective treatment may be critically
important for maximising long-term CPAP acceptance
and adherence.
Rescue and alternative therapies
Currently, CPAP clearly remains the first-line treatment
for OSA with a strong evidence base to support its use. In
patients who fail to accept or tolerate CPAP, the main
alternative treatments include surgery, mandibular
advancement splints, and weight loss. These may be
more appealing to patients who are poorly compliant
with CPAP, but effectiveness is more variable and some
risks are not trivial (e.g., surgery). In addition, poor
compliance may still be an issue and is more difficult to
monitor with other non-surgical treatments. Other
therapies, such as supine avoidance and interventions
targeting more specific underlying abnormalities, may be
suitable in carefully selected patients, but data to support
their use are currently lacking.
Implications for clinical practice
Successfully establishing patients on CPAP therapy is
challenging because of the variable nature of OSA,
symptomatology, co-morbidities, psychosocial factors,
and differing problems experienced by individual
patients when commencing CPAP treatment. Appropri-
ate education, mask and pressure selection, early
interventions to address problems and side-effects, and
follow-up support appear to be particularly important
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is still emerging, structured, multidisciplinary education
and early management using cognitive behaviour and
motivational approaches appear most likely to assist
patients to initially accept and then adhere to CPAP
treatment long-term [16,31,44]. Improved mask and
CPAP machine technology may help improve treatment
adherence in some patients, but non-technological
factors appear to be more important determinants of
longer-term CPAP adherence [16,62]. Evolving trends
towards simplified and faster diagnostic and manage-
ment strategies better equipped to deal with the large
community burden of OSA [64] could positively and
negatively impact adherence by addressing delays in
establishing treatment while potentially undermining
patient education and support [65]. Consequently,
appropriate clinical management addressing the main
barriers to treatment uptake and adherence is critically
important for successfully establishing and maintaining
patients on effective CPAP treatment long-term.
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